[1]
|
World Health Organization (1984) Collaborating Centers for International Drug Monitoring. World Health Organization, Geneva.
|
[2]
|
Sultana, J., Jerking, P. and Trifirò, G. (2013) Clinical and Economic Burden of Adverse Drug Reactions. Journal of Pharmacology and Pharmacotherapeutics, 4, S73-S77.
https://doi.org/10.4103/0976-500X.120957
|
[3]
|
Shehab, N., Lovegrove, M.C., Geller, A.I., Rose, K.O., Weidle, N.J. and Budnitz, D.S. (2016) US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. JAMA, 316, 2115-2125. https://doi.org/10.1001/jama.2016.16201
|
[4]
|
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K. and Breckenridge, A.M. (2004) Adverse Drug Reactions as Cause of Admission to Hospital: Prospective Analysis of 18820 Patients. BMJ, 329, 15-19.
https://doi.org/10.1136/bmj.329.7456.15
|
[5]
|
Wolfe, D., Yazdi, F., Kanji, S., Burry, L., Beck, A., Butler, C., Esmaeilisaraji, L., Hamel, C., Hersi, M., Skidmore, B., Moher, D. and Hutton, B. (2018) Incidence, Causes, and Consequences of Preventable Adverse Drug Reactions Occurring in Inpatients: A Systematic Review of Systematic Reviews. PLOS ONE, 13, e0205426.
https://doi.org/10.1371/journal.pone.0205426
|
[6]
|
Brennan, T.A., Leape, L.L., Laird, N.M., Hebert, L., Localio, A.R., Lawthers, A.G., et al. (1991) Incidence of Adverse Events and Negligence in Hospitalized Patients: Results of the Harvard Medical Practice Study I. The New England Journal of Medicine, 324, 370-376. https://doi.org/10.1056/NEJM199102073240604
|
[7]
|
Bates, D.W., Cullen, D., Laird, N., Petersen, L., Small, S., Servi, D., et al. (1995) Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention. JAMA, 274, 29-34. https://doi.org/10.1001/jama.1995.03530010043033
|
[8]
|
Lazarou, J., Pomeranz, B. and Corey, B. (1998) Incidence of Drug Adverse Reactions in Hospitalized Patients. A Meta-Analysis. JAMA, 279, 1200-1205.
https://doi.org/10.1001/jama.279.15.1200
|
[9]
|
Nolan, L. and O’Malley, K. (1988) Prescribing for the Elderly Part I: Sensitivity of the Elderly to Adverse Drug Reactions. Journal of the American Geriatrics Society, 36, 142-149. https://doi.org/10.1111/j.1532-5415.1988.tb01785.x
|
[10]
|
Gurwitz, J.H., Field, T.S., Harrold, L.R., Rothschild, J., Debellis, K., Seger, A.C., Cadoret, C., Fish, L.S., Garber, L., Kelleher, M. and Bates, D.W. (2003) Incidence and Preventability Adverse Drug Events among Older Patients in the Ambulatory Setting. JAMA, 289, 107-116. https://doi.org/10.1001/jama.289.9.1107
|
[11]
|
Otero, M.J., Toscano, G., Galván-Banqueri, M., Martinez-Sotelo, J. and Santos-Rubio, M.D. (2021) Utility of a Trigger Tool (TRIGGER-CHRON) to Detect Adverse Events Associated with High-Alert Medications in Patients with Multimorbidity. European Journal of Hospital Pharmacy, 28, E41-E46.
https://doi.org/10.1136/ejhpharm-2019-002126
|
[12]
|
Jick, H. (1984) Adverse Drug Reactions: The Magnitude of the Problem. Journal of Allergy and Clinical Immunology, 74, 555-557.
https://doi.org/10.1016/0091-6749(84)90106-4
|
[13]
|
Classen, D.C., Pestotnik, S.L., Evans, R.S., et al. (1997) Adverse Drug Events in Hospitalized Patients. Excess Length of Stay, Extra Costs, and Attributable Mortality. JAMA, 277, 301-306. https://doi.org/10.1001/jama.1997.03540280039031
|
[14]
|
Schatz, S.N. and Weber, R.J. (2015) Adverse Drug Reactions. In: Lee, M.W. and Murphy, J.E., Eds., PSAP 2015 Book 2 CNS/Pharmacy Practice, American College of Clinical Pharmacy, Lenexa, 5-26.
|
[15]
|
Panagioti, M., Khan, K., Keers, R.N., Abuzour, A., Phipps, D., Kontopantelis, E., et al. (2019) Prevalence, Severity, and Nature of Preventable Patient Harm across Medical Care Settings: Systematic Review and Meta-Analysis. BMJ, 366, L4185.
https://doi.org/10.1136/bmj.l4185
|
[16]
|
National Patient Safety Foundation (2015) Free from Harm: Accelerating Patient Safety Improvement Fifteen Years after to Err Is Human. National Patient Safety Foundation, Boston.
https://www.aorn.org/docs/default-source/guidelines-resources/position-statements/endorsed-documents/freefromharm_execsummary.pdf?sfvrsn=a09a1e82_1
|
[17]
|
Khalil, H., Shahid, M. and Roughead, L. (2017) Medication Safety Programs in Primary Care: A Scoping Review. JBI Database of Systematic Reviews and Implementation Reports, 15, 2512-2526. https://doi.org/10.11124/JBISRIR-2017-003436
|
[18]
|
Smith, J.C., Chen, Q., Denny, J.C., Roden, D.M., Johnson, K.B. and Miller, R.A. (2018) Evaluation of a Novel System to Enhance Clinicians’ Recognition of Preadmission Adverse Drug Reactions. Applied Clinical Informatics, 9, 313-325.
https://doi.org/10.1055/s-0038-1646963
|
[19]
|
Smith, J.C., Denny, J.C., Chen, Q., Nian, H., Spickard, A., Rosenbloom, S.T. and Miller, R.A. (2013) Lessons Learned from Developing a Drug Evidence Base to Support Pharmacovigilance. Applied Clinical Informatics, 4, 596-617.
https://doi.org/10.4338/ACI-2013-08-RA-0062
|
[20]
|
Wu, L., Ingle, T., Liu, Z., et al. (2019) Study of Serious Adverse Drug Reactions Using FDA-Approved Drug Labeling and MedDRA. BMC Bioinformatics, 20, Article No. 97. https://doi.org/10.1186/s12859-019-2628-5
|
[21]
|
Demner-Fushman, D., et al. (2018) A Dataset of 200 Structured Product Labels Annotated for Adverse Drug Reactions. Scientific Data, 5, Article ID: 180001.
https://doi.org/10.1038/sdata.2018.1
|
[22]
|
Wu, L.H., Ingle, T., Liu, Z.C., et al. (2019) Study of Serious Adverse Drug Reactions Using FDA-Approved Drug Labeling and MedDRA. BMC Bioinformatics, 20, Article No. 97. https://doi.org/10.1186/s12859-019-2628-5
|
[23]
|
Bates, D.W. (2000) Using Information Technology to Reduce Rates of Medication Errors in Hospitals. BMJ, 320, 788-791. https://doi.org/10.1136/bmj.320.7237.788
|
[24]
|
Harris, Y., Hu, D.J., Lee, C., Mistry, M., York, A. and Johnson, T.K. (2015) Advancing Medication Safety: Establishing a National Action Plan for Adverse Drug Event Prevention. The Joint Commission Journal on Quality and Patient Safety, 41, 351-360. https://doi.org/10.1016/S1553-7250(15)41046-3
|
[25]
|
https://www.cms.gov/search/cms?keys=adverse+drug+events
|
[26]
|
Marcum, Z.A., Arbogast, K.L., Behrens, M.C., Logsdon, M.W., Francis, S.D., Jeffery, S.M., Aspinall, S.L., Hanlon, J.T. and Handler, S.M. (2013) Utility of an Adverse Drug Event Trigger Tool in Veterans Affairs Nursing Facilities. The Consultant Pharmacist, 28, 99-109. https://doi.org/10.4140/TCP.n.2013.99
|
[27]
|
Classen, D.C., Pestotnik, S.L., Evans, R.S. and Burke, J.P. (2005) Computerized Surveillance of Adverse Drug Events in Hospital Patients. Quality & Safety in Health Care, 14, 221-225.
|
[28]
|
Habib, B., Tamblyn, R., Girard, N., Eguale, T. and Huang, A. (2021) Detection of Adverse Drug Events in E-Prescribing and Administrative Health Data: A Validation Study. BMC Health Services Research, 21, 376-403.
https://doi.org/10.1186/s12913-021-06346-y
|
[29]
|
O’Connor, M.N., O’Sullivan, D., Gallagher, P.F., Eustace, J., Byrne, S. and O’Mahony, D. (2016) Prevention of Hospital-Acquired Adverse Drug Reactions in Older People Using Screening Tool of Older Persons’ Prescriptions and Screening Tool to Alert to Right Treatment Criteria: A Cluster Randomized Controlled Trial. Journal of the American Geriatrics Society, 64, 1558-1566. https://doi.org/10.1111/jgs.14312
|
[30]
|
PDR Drug Information Fully Searchable Fully Digital. http://www.pdr.net
|
[31]
|
https://online.lexi.com/lco/action/home
|
[32]
|
https://www.micromedexsolutions.com/micromedex2/librarian
|
[33]
|
Recent Alerts. https://www.dynamed.com/
|
[34]
|
Novel Coronavirus Resource Center. https://reference.medscape.com/
|
[35]
|
Drugs. https://online.epocrates.com/drugs
|
[36]
|
UpToDate: Industry-Leading Clinical Decision Support.
https://www.wolterskluwer.com/en/solutions/uptodate
|
[37]
|
https://dailymed.nlm.nih.gov/dailymed/
|
[38]
|
Questions and Answers on FDA’s Adverse Event Reporting System (FAERS).
https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/
|
[39]
|
DeRhodes, K.H. (2019) the Dangers of Ignoring the Beers Criteria—The Prescribing Cascade. JAMA Internal Medicine, 179, 863-864.
https://doi.org/10.1001/jamainternmed.2019.1288
|
[40]
|
Nguyen, P.V. and Spinelli, C. (2016) Prescribing Cascade in an Elderly Woman. Canadian Pharmacists Journal, 149, 122-124.
https://doi.org/10.1177/1715163516640811
|
[41]
|
The Prescribing Cascade.
https://www.nps.org.au/assets/bfed344b681dd636-b041584d99e7-ca3f75bcf6b64e70d9dde28acdc1db3afe4ec255b4828f2084ec8c611b0c.pdf
|
[42]
|
Sternberg, S.A., Guy-Alfandary, S. and Rochon, P.A. (2021) Prescribing Cascades in Older Adults. Canadian Medical Association Journal, 193, E215.
https://doi.org/10.1503/cmaj.201564
|
[43]
|
Brody, J. (2020) The Risks of the Prescribing Cascade. The New York Times.
|
[44]
|
Wang, J., Shen, J.Y., Conwell, Y., Podiatry, E.J., Caprio, T.V., Nathan, K., Yu, F., Rams, D.E.E., Fick, D.M., Mixon, A.S. and Simmons, S.F. (2022) Implementation Considerations of Deprescribing Interventions: A Scoping Review. Journal of Internal Medicine. https://doi.org/10.1111/joim.13599
|
[45]
|
National Action Plan for Adverse Drug Event Prevention.
https://health.gov/sites/default/files/2019-09/ADE-Action-Plan-Introduction.pdf
|
[46]
|
Department of Health and Human Services Part 1. Overview Information.
https://grants.nih.gov/grants/guide/pa-files/pa-20-028.html
|
[47]
|
AHRQ Grants by State.
https://www.ahrq.gov/funding/grant-mgmt/grants-by-state.html
|
[48]
|
Gandhi, T.K., Weingart, S.N., Borus, J., Seger, A.C., Peterson, J., Burdick, E., Seger, D.L., Shu, K., Federico, F., Leape, L.L. and Bates, D.W. (2003) Adverse Drug Events in Ambulatory Care. The New England Journal of Medicine, 348, 1556-1564.
https://doi.org/10.1056/NEJMsa020703
|
[49]
|
Gandhi, T.K., Burstin, H.R., Cook, E.F., Puopolo, A.L., Haas, J.S., Brennan, T.A. and Bates, D.W. (2000) Drug Complications in Outpatients. Journal of General Internal Medicine, 15, 149-154. https://doi.org/10.1046/j.1525-1497.2000.04199.x
|
[50]
|
Pitrou, I., Boutron, I., Ahmad, N. and Ravaud, P. (2009) Reporting of Safety Results in Published Reports of Randomized Controlled Trials. Archives of Internal Medicine, 169, 1756-1761. https://doi.org/10.1001/archinternmed.2009.306
|
[51]
|
Cross, C. (2013) Drug Reporting May Be Mandatory for Doctors. Canadian Medical Association Journal, 185, 866. https://doi.org/10.1503/cmaj.109-4487
|
[52]
|
Step 5: FDA Post-Market Drug Safety Monitoring.
https://www.fda.gov/patients/drug-development-process/step-5-fda-post-market-drug-safety-monitoring
|
[53]
|
MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
|
[54]
|
Alomar, M., Tawfiq, A.M., Hassan, N. and Palaian, S. (2020) Post Marketing Surveillance of Suspected Adverse Drug Reactions through Spontaneous Reporting: Current Status, Challenges and the Future. Therapeutic Advances in Drug Safety, 11, 1-11. https://doi.org/10.1177/2042098620938595
|
[55]
|
Postmarketing Surveillance.
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/postmarketing-surveillance
|
[56]
|
Moore, V.R., Glassman, P.A., Au, A., Good, C.B., Leadholm, T.C. and Cunningham, F.E. (2019) Adverse Drug Reactions in the Veterans Affairs Healthcare System: Frequency, Severity, and Causative Medications Analyzed By Patient Age. American Journal of Health-System Pharmacy, 76, 312-319.
https://doi.org/10.1093/ajhp/zxy059
|
[57]
|
Adverse Drug Event Reporting and Monitoring.
https://www.va.gov/vhapublications/viewpublication.asp?pub_id=8831
|
[58]
|
Bruno, H., Stricker, C. and Psaty, B. (2004) Detection, Verification, and Quantification of Adverse Drug Reactions. British Medical Journal, 329, 44-47.
https://doi.org/10.1136/bmj.329.7456.44
|
[59]
|
Agbabiaka, T.B., Savovic, J. and Ernst, E. (2008) Methods for Causality Assessment of Adverse Drug Reactions: A Systematic Review. Drug Safety, 31, 21-37.
https://doi.org/10.2165/00002018-200831010-00003
|
[60]
|
Wu, L., Ingle, T., Liu, Z. et al. (2019) Study of Serious Adverse Drug Reactions Using FDA-Approved Drug Labeling and MedDRA. BMC Bioinformatics, 20, Article No. 97. https://doi.org/10.1186/s12859-019-2628-5
|
[61]
|
Lee, C.Y. and Chen, Y.P. (2021) Prediction of Drug Adverse Events Using Deep Learning in Pharmaceutical Discovery. Briefings in Bioinformatics, 22, 1884-1901.
https://doi.org/10.1093/bib/bbaa040
|
[62]
|
Yu, Z., Wu, Z., Li, W., Liu, G. and Tang, Y. (2022) ADENet: A Novel Network-Based Inference Method for Prediction of Drug Adverse Events. Briefings in Bioinformatics, 23, bbab580. https://doi.org/10.1093/bib/bbab580
|